# Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome

> **NCT01104415** · PHASE2 · COMPLETED · sponsor: **Lexicon Pharmaceuticals** · enrollment: 15 (actual)

## Conditions studied

- Carcinoid Syndrome

## Interventions

- **DRUG:** Telotristat etiprate

## Key facts

- **NCT ID:** NCT01104415
- **Lead sponsor:** Lexicon Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06-15
- **Primary completion:** 2014-02-12
- **Final completion:** 2014-02-12
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2019-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01104415

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01104415, "Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01104415. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*